This ongoing Program Project Grant was originally initiated in order to develop a team approach to clarifying the mechanisms by which tumor cells affect the skeleton and cause disastrous clinical consequences such as hypercalcemia, bone pain and susceptibility to fracture. During the original project period, we gathered a team with expertise in identifying factors which were involved in disrupting calcium homeostasis and affecting bone metabolism. Recent progress in this field has been dramatic and we now wish to extend our studies on characterization of the effects of the heterogeneous tumor factors which can disturb calcium homeostasis. Since the time of our original application, a number of tumor factors associated with hypercalcemia have been identified, so that it is now possible to characterize fully the effects of these factors not only on bone metabolism in vitro, but also on renal function and calcium homeostasis in vivo. As a consequence, we have gathered a team of investigators with the skills in bone cell biology, protein purification, molecular biology, bone histomorphometry, and renal physiology to accomplish our goals.
The specific aims of this application are 1) to identify completely the tumor-associated factors which are responsible for causing hypercalcemia in specific tumors associated with the humoral hypercalcemia of malignancy, breast cancer and in hematologic malignancies such as myeloma, and 2) to determine the effects of these specific tumor-associated peptides (alone and in combination) on calcium homeostasis in vivo, and the relative importance of their specific effects on bone and renal function by our in vitro and in vivo models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA040035-08S1
Application #
2090072
Study Section
Special Emphasis Panel (SRC (G2))
Project Start
1985-09-30
Project End
1995-05-31
Budget Start
1993-06-01
Budget End
1995-05-31
Support Year
8
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Arnold Egloff, Shanna A; Du, Liping; Loomans, Holli A et al. (2017) Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget 8:722-741
Arnold, Shanna A; Loomans, Holli A; Ketova, Tatiana et al. (2016) Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis 33:29-44
Preston Campbell, J; Mulcrone, P; Masood, S K et al. (2015) TRIzol and Alu qPCR-based quantification of metastatic seeding within the skeleton. Sci Rep 5:12635
Sharma, Ramaswamy; Williams, Paul J; Gupta, Anjana et al. (2015) A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, ?-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget 6:21589-602
Seeley, Erin H; Wilson, Kevin J; Yankeelov, Thomas E et al. (2014) Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease. Bone 61:208-16
Johnson, Rachelle W; Merkel, Alyssa R; Page, Jonathan M et al. (2014) Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis 31:945-59
Ding, Hao; Nyman, Jeffry S; Sterling, Julie A et al. (2014) Development of Raman spectral markers to assess metastatic bone in breast cancer. J Biomed Opt 19:111606
Hansen, Amanda G; Arnold, Shanna A; Jiang, Ming et al. (2014) ALCAM/CD166 is a TGF-?-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res 74:1404-15
Waning, David L; Mohammad, Khalid S; Guise, Theresa A (2013) Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell 24:407-9
Jin, Renjie; Sterling, Julie A; Edwards, James R et al. (2013) Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One 8:e60983

Showing the most recent 10 out of 210 publications